Celadon Pharmaceuticals PLC
LSE:CEL
Celadon Pharmaceuticals PLC
Research & Development
Celadon Pharmaceuticals PLC
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
Research & Development
-£320.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Croda International PLC
LSE:CRDA
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Science in Sport PLC
LSE:SIS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chill Brands Group PLC
LSE:CHLL
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Venture Life Group PLC
LSE:VLG
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Provexis PLC
LSE:PXS
|
Research & Development
-£310k
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
Celadon Pharmaceuticals PLC
Glance View
Summerway Capital Plc engages in acquiring companies or businesses that has the potential for strategic, operational, and performance improvement. The firm is engaged in research, cultivation, manufacturing and supply of cannabinoid-based medicines. The firm is focused on growing indoor hydroponic cannabis initially for the chronic pain market. The company is also focused on improving the quality of life for chronic pain sufferers, as well as exploring the potential of cannabinoid-based medicines for other conditions such as autism. The firm's facility comprises an indoor, closed-loop hydroponic system to ensure cannabis plants are cultivated under a highly specific climate, light and with irrigation control. The firm's subsidiary, LVL Health is a medical cannabis clinic for chronic pain that owns a medicines and healthcare products regulatory agency (MHRA) conditionally approved cannabis trial using cannabis-based medicinal products to treat chronic pain in the United Kingdom.
See Also
What is Celadon Pharmaceuticals PLC's Research & Development?
Research & Development
-320.7m
GBP
Based on the financial report for Dec 31, 2024, Celadon Pharmaceuticals PLC's Research & Development amounts to -320.7m GBP.
What is Celadon Pharmaceuticals PLC's Research & Development growth rate?
Research & Development CAGR 1Y
17%
Over the last year, the Research & Development growth was 17%.
